560 related articles for article (PubMed ID: 19282169)
1. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
Shirao K; Nishida T; Doi T; Komatsu Y; Muro K; Li Y; Ueda E; Ohtsu A
Invest New Drugs; 2010 Dec; 28(6):866-75. PubMed ID: 19730791
[TBL] [Abstract][Full Text] [Related]
3. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Li J; Gao J; Hong J; Shen L
Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
8. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
9. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Demetri GD; Heinrich MC; Fletcher JA; Fletcher CD; Van den Abbeele AD; Corless CL; Antonescu CR; George S; Morgan JA; Chen MH; Bello CL; Huang X; Cohen DP; Baum CM; Maki RG
Clin Cancer Res; 2009 Sep; 15(18):5902-9. PubMed ID: 19737946
[TBL] [Abstract][Full Text] [Related]
10. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV
Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195
[TBL] [Abstract][Full Text] [Related]
11. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
13. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
[TBL] [Abstract][Full Text] [Related]
15. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Benjamin RS; Schöffski P; Hartmann JT; Van Oosterom A; Bui BN; Duyster J; Schuetze S; Blay JY; Reichardt P; Rosen LS; Skubitz K; McCoy S; Sun YN; Stepan DE; Baker L
Cancer Chemother Pharmacol; 2011 Jul; 68(1):69-77. PubMed ID: 20838998
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
18. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
19. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]